In trastuzumab-resistant ErbB2-positive breast cancer cells, the improved glycolytic rate is regulated by heat shock factor 1 and LDHA and inhibition of glycolysis with 2-DG and the LDH inhibitor oxamate by-pass trastuzumab resistance (145). The gene discussed is ERBB2; the disease is breast carcinoma.